Product
IBI333
1 clinical trial
1 indication
Indication
Age-Related Macular DegenerationClinical trial
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)Status: Active (not recruiting), Estimated PCD: 2023-12-07